Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma will have priority rights for the commercialisation and manufacture of SK Biopharmaceuticals’ current and future pipeline of innovative products for 17 countries in the MENA region. In addition, Hikma will have the exclusive rights to manufacture and commercialise SK Biopharmaceuticals’ first pipeline product, cenobamate, an innovative anti-seizure medication for patients with epilepsy, in MENA markets. SK Biopharmaceuticals also aims to expand from small molecule targeted therapy into biologics and we are excited to be their partner to ensure patients’ access to these innovative therapies in MENA.”About CenobamateCenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them.

Source: The North Africa Journal August 18, 2023 09:05 UTC